^
    23h
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    24h
    MRD Detection by NGS in Pediatric T-ALL (clinicaltrials.gov)
    P=N/A, N=148, Completed, The Children's Hospital of Zhejiang University School of Medicine | N=69 --> 148 | Trial completion date: Dec 2022 --> Dec 2025
    Enrollment change • Trial completion date • IO biomarker
    1d
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pomalidomide
    1d
    Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL) (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New trial
    1d
    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed
    2d
    CD7-Specific Polymersomal Vincristine Delivery Potentiates Chemotherapy in T‑Cell Acute Lymphoblastic Leukemia. (PubMed, Polym Sci Technol)
    Interestingly, aCD7P-VCR treatment substantially reduced leukemia progression and invasion in the orthotopic CCRF-CEM T-ALL model without toxic effects, leading to significantly longer survival than clinically used VCR and nontargeted P-VCR. aCD7P-VCR is expected to provide an effective and targeted therapeutic approach for T-ALL.
    Journal
    |
    CD7 (CD7 Molecule)
    |
    vincristine
    2d
    A RiboCancer cell line panel reveals that CLL-associated Rps15 mutations translationally rewire transcription through codon-specific tRNA accommodation defects. (PubMed, Hemasphere)
    By developing and characterizing a unique RiboCancer cell line panel, we mapped translational rewiring driven by the most frequent somatic RP mutations. We provide unprecedented mechanistic insights into translation defects induced by CLL-associated Rps15 mutations, and reveal an intriguing translation-based rewiring of transcription in CLL.
    Preclinical • Journal
    |
    RUNX3 (RUNX Family Transcription Factor 3) • RPL10 (Ribosomal Protein L10) • RPL5 (Ribosomal Protein L5) • RPL11 (Ribosomal Protein L11) • RPL22 (Ribosomal Protein L22)
    2d
    Not Missing the Notch: Detection Challenges of Juxtamembrane NOTCH1 Variant Detection in T-Cell Acute Lymphoblastic Leukemia. (PubMed, J Clin Lab Anal)
    Detection of NOTCH1 JME-ITDs depends strongly on variant-calling strategy. Combining haplotype-based callers with split-read structural variant tools may reduce false negatives and improve detection of clinically relevant insertions in diagnostic NGS pipelines.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • NOTCH1 (Notch 1)
    |
    PTEN mutation
    |
    OncoKitDx
    2d
    A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia. (PubMed, Leukemia)
    Using T-ALL PDXs we further show that (i) ADC-CD7-BCL-XLi displays potent anti-leukemic activity and is devoid of toxicity to platelets; (ii) ADC-CD7-BCL-XLi acts synergistically with venetoclax, a BCL-2 selective antagonist, to prolong leukemia remission and mouse survival; (iii) the anti-leukemic effect of the ADC-CD7-BCL-XLi+venetoclax combination can lead to cure when combined with chemotherapy. These pre-clinical data strongly support the evaluation of ADC-CD7-BCL-XLi in T-ALL patients, including as a potential bridging option to curative hematopoietic stem cell transplantation (HSCT).
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CD7 (CD7 Molecule)
    |
    Venclexta (venetoclax)
    2d
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    3d
    ALL2620: The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in patients: MRD positive (persistent or relapsed), patients after haematological and extra-haematologicalnrelapse and patients who do not have never achieved remission after any previous treatment. (2024-516868-28-00)
    P1/2, N=67, Completed, Fondazione Gimema Franco Mandelli Onlus | Active, not recruiting --> Completed
    Trial completion • Minimal residual disease
    |
    cytarabine • Iclusig (ponatinib) • vincristine • prednisone
    3d
    PONAT-14-25: An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code 06739-024, Vargem Grande Paulista SP CNPJ No. 21,896,000/0001-91, in healthy adult, human subjects under fasting condition. (2025-524311-37-00)
    P1, N=56, Recruiting, Sun Pharmaceutical Industries Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iclusig (ponatinib)